Skip to content
Search

Latest Stories

Those with type 2 diabetes are more at risk of Parkinson's

If you have been detected with Type-2 diabetes at an early age then you are more at risk of developing Parkinson's disease later in life, a new study has revealed.

The findings stated that those with Type-2 diabetes had a 31 per cent increased risk of Parkinson's disease than those without diabetes. The risk was higher for younger people aged between 25 and 44. The study also revealed that those with complications from diabetes had a 49 per cent greater risk of being diagnosed with Parkinson's.


The study was conducted by a team from University College London, the University of Oxford and Queen Mary University of London.

“We can now say more definitely that there is a link between diabetes and Parkinson’s but we need to do more research to understand the relationship — whether it’s due to genetics, the effect of diabetes on the brain or both,” the study’s lead author, Professor Tom Warner of UCL, said. “While the association is substantial, it’s still clear that most people with type 2 diabetes will not go on to develop Parkinson’s.”

The result of the study was published in the journal Neurology.

The study was conducted using hospital records to follow 2,017,115 people with type 2 diabetes between 1999 and 2011, and it compared them with 6,173,208 people without the disease.

Among those with diabetes, 14,252 had a diagnosis or were later diagnosed with Parkinson’s disease, compared with 20,878 in the comparison group.

These findings could help improve treatments for both Type-2 diabetes and Parkinson's.

“We’ve added to evidence that diabetes and Parkinson’s are linked, which in turn raises the possibility that they may respond to common therapies,” Dr Alastair Noyce, a co-author of the most recent study, said. “We hope that furthering our understanding of the relationship between the two diseases could help improve treatments for both conditions.”

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Serena Williams

Williams explained that her weight challenges began after the birth of her first daughter

Getty Images

Serena Williams says GLP-1 made her feel light physically and mentally after 31lb loss

Highlights:

  • Serena Williams reveals she has lost more than 31lbs using a GLP-1 medication
  • The tennis legend says the treatment enhanced her existing healthy lifestyle
  • She stresses that weight loss should not change self-image or self-confidence

Serena Williams has revealed she has lost more than 31lbs after turning to a weight-loss medication, saying the treatment has transformed both her body and her mindset.

The 23-time Grand Slam champion, 43, told PEOPLE that using a GLP-1 medication — a type of injection that works by regulating appetite — has helped enhance the healthy lifestyle she already maintained through diet and exercise.

Keep ReadingShow less